Compound ID | 348
Class: Beta-lactam (cephalosporin)
Spectrum of activity: | Gram-positive & Gram-negative |
Details of activity: | Use against Enteric infections |
Institute where first reported: | GSK, USA |
Year first mentioned: | 1989 |
Highest developmental phase: | Phase 1 |
Development status: | Inactive |
Reason Dropped: | Catechol-containing compounds: MIC50s « 0.008-0.39 μg/mL against P. aeruginosa are superior to that of ceftazidime. These catecholic ,B-lactams were expected to show superior therapeutic responses against pseudomonal infections in humans, but they were discontinued due to side effects or unfavourable pharmokinetics in phase I/ II studies (2) |
Chemical structure(s): | |
Canonical SMILES: | C1=C(C=C(C(=C1)O)O)[C@@H](C(=O)O)O/N=C(/C2=CSC(=N2)N)\C(=O)N[C@@H]3C(=O)N4C(=CCS[C@H]34)C(=O)O |
Isomeric SMILES: | C1C=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)/C(=N\O[C@@H](C3=CC(=C(C=C3)O)O)C(=O)O)/C4=CSC(=N4)N)C(=O)O |
InChI: | InChI=1S/C20H17N5O9S2/c21-20-22-8(6-36-20)12(24-34-14(19(32)33)7-1-2-10(26)11(27)5-7)15(28)23-13-16(29)25-9(18(30)31)3-4-35-17(13)25/h1-3,5-6,13-14,17,26-27H,4H2,(H2,21,22)(H,23,28)(H,30,31)(H,32,33)/b24-12-/t13-,14+,17-/m1/s1 |
InChI Key: | ILZCDOYRDFDUPN-XUQRFURESA-N |
Structure link: | https://pubchem.ncbi.nlm.nih.gov/compound/9807169 |
External links: | |
Guide to Pharmacology: | cefetecol |
Citations: |
|